Loading
A phase 2 trial of SHR-A1904 for Injection in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer is a phase 2 interventional study registered as NCT07450976 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 151 participants planned, started 2026-03-25 and due to reach its primary completion in 2030-12. Interventions recorded: SHR-A1904 for Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/